Amneal Pharmaceuticals financials
$20.20−1.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B |
| Gross profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M | $628.4M | $353.0M | $716.4M |
| Gross margin | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% | 31.5% | 21.7% | 43.1% |
| Operating income | $388.9M | $248.4M | $188.7M | -$94.9M | $152.7M | $91.2M | -$248.7M | -$19.7M |
| Net income | $72.1M | -$116.9M | -$84.0M | -$130.0M | $10.6M | $91.1M | -$361.9M | -$20.9M |
| Net margin | 2.4% | −4.2% | −3.5% | −5.9% | 0.5% | 4.6% | −22.3% | −1.3% |
| Diluted EPS | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 |
| EBITDA | $616.2M | $583.6M | $452.5M | $429.6M | $421.7M | $346.5M | $104.7M | $425.9M |
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M | $379.0M | $1.7M | $250.2M |
| Free cash flow | $269.9M | $243.2M | $302.4M | $16.3M | $190.9M | $322.6M | -$45.5M | $167.1M |
| Diluted shares | 324.8M | 309.0M | 176.1M | 150.9M | 151.8M | 148.9M | 132.1M | 127.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M | $341.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $2.57B | $2.55B | $2.66B | $2.75B | $2.77B | $2.78B |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B |
| Total liabilities | $3.67B | $3.55B | $3.41B | $3.59B | $3.56B | $3.65B |
| Shareholders' equity | $6.0M | -$109.5M | $20.0M | $184.0M | $367.0M | $344.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology